GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Cyclically Adjusted PS Ratio

The Medicines Co (The Medicines Co) Cyclically Adjusted PS Ratio : (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


The Medicines Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for The Medicines Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Cyclically Adjusted PS Ratio Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of The Medicines Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Medicines Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where The Medicines Co's Cyclically Adjusted PS Ratio falls into.



The Medicines Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

The Medicines Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, The Medicines Co's adjusted Revenue per Share data for the three months ended in Sep. 2019 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=0/108.3294*108.3294
=0.000

Current CPI (Sep. 2019) = 108.3294.

The Medicines Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 1.948 91.111 2.316
201003 1.936 91.821 2.284
201006 2.081 91.962 2.451
201009 1.982 92.162 2.330
201012 2.228 92.474 2.610
201103 2.072 94.283 2.381
201106 2.202 95.235 2.505
201109 2.226 95.727 2.519
201112 2.408 95.213 2.740
201203 2.274 96.783 2.545
201206 2.443 96.819 2.733
201209 2.480 97.633 2.752
201212 2.899 96.871 3.242
201303 2.882 98.209 3.179
201306 2.868 98.518 3.154
201309 2.759 98.790 3.025
201312 1.762 98.326 1.941
201403 2.763 99.695 3.002
201406 2.854 100.560 3.075
201409 2.671 100.428 2.881
201412 1.716 99.070 1.876
201503 1.645 99.621 1.789
201506 1.131 100.684 1.217
201509 0.852 100.392 0.919
201512 0.764 99.792 0.829
201603 0.727 100.470 0.784
201606 0.755 101.688 0.804
201609 0.536 101.861 0.570
201612 0.007 101.863 0.007
201703 0.246 102.862 0.259
201706 0.151 103.349 0.158
201709 0.109 104.136 0.113
201712 0.116 104.011 0.121
201803 0.105 105.290 0.108
201806 0.023 106.317 0.023
201809 -0.045 106.507 -0.046
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


The Medicines Co  (NAS:MDCO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


The Medicines Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of The Medicines Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010